Vidac Pharma receives Japanese Patent Office Notice of Allowance for VDA-1275 cancer drug candidate London (UK), March 27, 2024 (07:30 CET) “ Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G;...
Vidac secures approval for study of lead asset in Cutaneous T-Cell Lymphoma
London (UK), February 19, 2024, 7:30 am CET Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma reports positive interim Phase 2a data in VDA-1102
London (UK), December 19, 2023 “ Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed...